Use of ave0010 for the treatment of diabetes mellitus type 2

Abstract

The present invention refers to the use of Lixisenatide or/and a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of diabetes mellitus type 2, for inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.

1 : A method of improving glycemic control in a patient with untreated type 2 diabetes mellitus comprising:
 administering once daily to the patient a therapeutically effective amount of desPro 36 Exendin-4(1-39)-Lys 6 -NH 2  (“lixisenatide”) and/or a pharmaceutically acceptable salt thereof;   wherein the improvement of glycemic control in the patient leads to a significant reduction of HbA1c.   
     
     
         2 : The method of  claim 1 , wherein the HbA1c is reduced by about 0.73%. 
     
     
         3 : The method of  claim 1 , wherein the HbA1c is reduced by about 0.61% to about 0.84%. 
     
     
         4 : The method of  claim 1 , wherein the HbA1c is reduced by about 0.85%. 
     
     
         5 : The method of  claim 1 , wherein the HbA1c is reduced by about 0.73% to about 0.969%. 
     
     
         6 : The method of  claim 1 , wherein the HbA1c is reduced by at least about 0.6%. 
     
     
         7 : A method of improving glycemic control in a patient with untreated type 2 diabetes mellitus comprising:
 administering once daily to the patient a therapeutically effective amount of desPro 36 Exendin-4(1-39)-Lys 6 -NH 2  (“lixisenatide”) and/or a pharmaceutically acceptable salt thereof;   wherein the improvement of glycemic control in the patient leads to a significant reduction of glucose excursion (mmol/L).   
     
     
         8 : The method of  claim 7 , wherein the glucose excursion is reduced by about 3.77 mmol/L. 
     
     
         9 : The method of  claim 7 , wherein the glucose excursion is reduced by about 3.316 mmol/L to about 4.224 mmol/L. 
     
     
         10 : The method of  claim 7 , wherein the glucose excursion is reduced by about 4.36 mmol/L. 
     
     
         11 : The method of  claim 7 , wherein the glucose excursion is reduced by about 3.924 mmol/L to about 4.796 mmol/L. 
     
     
         12 : The method of  claim 7 , wherein the glucose excursion is reduced by at least about 3.3 mmol/L. 
     
     
         13 : The method of  claim 7 , wherein the glucose excursion is reduced by about 75%.